Low-Dose Edoxaban lowers risk of embolism among Elderly with atrial fibrillation: JAMA
In a new study conducted by Shintaro Akashi and colleagues, it was found that older individuals with atrial fibrillation (AF) who took low-dose edoxaban (15 mg) had a lower risk of stroke or systemic embolism than those who took a placebo. The findings of this study were published in the Journal of American Medical Association.
Atrial fibrillation is more prevalent in elderly and debilitated people and rises with age. Data on the effectiveness of oral anticoagulants (OACs) in extremely old individuals with AF who are ineligible for traditional anticoagulant therapy, however, are scarce. In order to evaluate extremely low dosage edoxaban (15 mg daily) with placebo across frailty status, including each of the 5 frailty assessment criteria, among AF patients participating in the ELDERCARE-AF trial, this study was carried out.
This is a cohort analysis using data from ELDERCARE-AF, a double-blind, multicenter, randomized, placebo-controlled phase 3 investigation of Japanese patients with AF 80 years of age or older who were ineligible for OACs at dosages allowed for stroke prevention due to their significant bleeding risks. Edoxaban or a placebo was randomly given to eligible patients (1:1). The last patient was followed up on December 27, 2019, and the study ran from August 5, 2016, to November 5, 2019. The period of data analysis lasted from February 2021 to February 2022. Major bleeding served as the key safety endpoint while the composite of stroke or systemic embolism served as the primary effectiveness endpoint.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.